Founded in 2013, Nightingale Health is a Finnish biotech company aiming to solve the world’s number one health issue – chronic diseases. With a proprietary blood analysis platform, the company can improve risk prediction of diseases such as cardiovascular diseases and diabetes.
Nightingale is built on an unrivalled scientific foundation comprising of an interdisciplinary team of experts in computational medicine, healthcare IT and business. It is headquartered with two flagship laboratory facilities in Finland, along with two franchising laboratories in the UK. Nightingale routinely provides services for academic researchers, healthcare professionals and industrial R&D customers internationally.
Nightingale’s biomarker profiling technology measures metabolic biomarkers that recent studies have found to be predictive of future risk for heart disease, type 2 diabetes and many other common chronic diseases. Until recently, technological constraints and prohibitive costs have prevented the analysis of comprehensive biomarker data from large-scale population collections. Nightingale’s technology now makes this viable by measuring over 220 metabolic biomarkers from a single blood sample.
Nightingale is to perform large-scale metabolic profiling of the Mexico City Prospective Study cohort by analyzing the biomarker profiles of blood samples from a cohort of 150,000 study participants, within 12 months, allowing researchers to start investigating the novel dataset promptly.
“The Mexico City Prospective Study provides researchers with a unique opportunity to investigate the major causes of death in a Hispanic population. Biomarker profiling will allow us to better understand how lifestyle, environment and genetics combine to cause diseases such as cardiovascular disease in a population with high levels of obesity and diabetes.” – Jonathan Emberson, Associate Professor, Medical Statistics and Epidemiology in the Nuffield Department of Population Health, University of Oxford, UK
“The chronic disease burden is global. Therefore, it’s essential to study populations across the globe capturing ethnic and socio-economic differences that underlie disease risk,” … “Nightingale’s analysis of metabolic profiles from this cohort of 150,000 will facilitate the evaluation of effective prevention strategies and treatments for the local population. We believe that this novel initiative is a concrete step towards making chronic disease prevention a global effort.” – Teemu Suna, CEO and Founder, Nightingale Health.
Sources
